These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 33731992

  • 1. The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study.
    Requena G, Dedman D, Quint JK, Ghosh RE, Williams R, Pimenta JM.
    Int J Chron Obstruct Pulmon Dis; 2021; 16():629-642. PubMed ID: 33731992
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol.
    Moretz C, Bengtson LG, Sharpsten L, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R.
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2047-2060. PubMed ID: 31564852
    [Abstract] [Full Text] [Related]

  • 3. Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany.
    Beeh KM, Rothnie KJ, Claussen J, Hardtstock F, Knapp RK, Wilke T, Czira A, Compton C, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2024; 19():945-956. PubMed ID: 38646606
    [Abstract] [Full Text] [Related]

  • 4. Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study.
    Slade D, Ray R, Moretz C, Germain G, Laliberté F, Shen Q, Duh MS, Mahendran M, Hahn B.
    BMC Pulm Med; 2021 Jul 31; 21(1):253. PubMed ID: 34332555
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England.
    Czira A, Requena G, Banks V, Wood R, Tritton T, Castillo CM, Yeap J, Wild R, Compton C, Rothnie KJ, Herth F, Quint JK, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2023 Jul 31; 18():643-659. PubMed ID: 37155496
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study.
    Zheng J, Zhong N, Newlands A, Church A, Goh AH.
    Int J Chron Obstruct Pulmon Dis; 2015 Jul 31; 10():1753-67. PubMed ID: 26366068
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR.
    Int J Chron Obstruct Pulmon Dis; 2017 Jul 31; 12():997-1008. PubMed ID: 28392684
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England.
    Requena G, Czira A, Banks V, Wood R, Tritton T, Castillo CM, Yeap J, Wild R, Compton C, Rothnie KJ, Herth F, Quint JK, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2023 Jul 31; 18():1431-1444. PubMed ID: 37465818
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of Adherence and Persistence to Triple Therapy in Patients with COPD: A German Claims Data Study.
    Vogelmeier CF, Beeh KM, Schultze M, Kossack N, Richter LM, Claussen J, Compton C, Noorduyn SG, Ismaila AS, Requena G.
    Int J Chron Obstruct Pulmon Dis; 2024 Jul 31; 19():1835-1848. PubMed ID: 39140078
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A.
    Respir Med; 2015 Sep 31; 109(9):1155-63. PubMed ID: 26117292
    [Abstract] [Full Text] [Related]

  • 13. Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
    Kerwin E, Ferguson GT, Sanjar S, Goodin T, Yadao A, Fogel R, Maitra S, Sen B, Ayers T, Banerji D.
    Lung; 2017 Dec 31; 195(6):739-747. PubMed ID: 28993871
    [Abstract] [Full Text] [Related]

  • 14. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
    Hanania NA, Mannino DM, Criner GJ, Dransfield MT, Han MK, Jones CE, Kilbride S, Lomas DA, Martin N, Martinez FJ, Singh D, Wise RA, Halpin DMG, Lima R, Lipson DA.
    Chest; 2021 Mar 31; 159(3):985-995. PubMed ID: 33031829
    [Abstract] [Full Text] [Related]

  • 15. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
    Kelleher D, Tombs L, Preece A, Brealey N, Mehta R.
    Pulm Pharmacol Ther; 2014 Oct 31; 29(1):49-57. PubMed ID: 25020273
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials.
    Ray R, Tombs L, Naya I, Compton C, Lipson DA, Boucot I.
    Pulm Pharmacol Ther; 2019 Aug 31; 57():101802. PubMed ID: 31096036
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
    Feldman G, Walker RR, Brooks J, Mehta R, Crater G.
    Pulm Pharmacol Ther; 2012 Dec 31; 25(6):465-71. PubMed ID: 22955035
    [Abstract] [Full Text] [Related]

  • 19. Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD.
    Albertson TE, Bowman WS, Harper RW, Godbout RM, Murin S.
    Int J Chron Obstruct Pulmon Dis; 2019 Dec 31; 14():1251-1265. PubMed ID: 31239659
    [Abstract] [Full Text] [Related]

  • 20. Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study.
    Mannino D, Bogart M, Wu B, Germain G, Laliberté F, MacKnight SD, Jung Y, Stiegler M, Duh MS.
    Respir Med; 2022 Jun 31; 197():106807. PubMed ID: 35429764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.